Accretion Pharmaceuticals Ltd. (ACCPL-ST) Share Price Within 2% of 52-Week High

Accretion Pharmaceuticals Ltd. Share Price is Rs 190, with the stock trading within 2% of its 52-week high. Market capitalisation stands at Rs 211.26 crore.

Accretion Pharmaceuticals Ltd. Share Price is at Rs 190, and the stock is trading within 2% of its 52-week high, according to the Univest screener. With a market capitalisation of Rs 211.26 crore, the move puts the small-cap Healthcare counter back on investor watchlists because proximity to a one-year peak often signals sustained price interest, even when the supplied data does not establish a company-specific catalyst.

For readers tracking Accretion Pharmaceuticals Ltd. Share Price Today, the verified event is straightforward: the stock qualified on the Univest screen at a last traded price of Rs 190 on 11 August 2026 at 9:30:37 AM IST. The qualification confirms only that the share is within striking distance of its yearly high; it does not by itself confirm a breakout or a new high.

That distinction matters. A stock near its 52-week high can attract attention because market participants often compare price strength with valuation, profitability and sector positioning. In this case, the available data gives a useful starting point through P/E, P/B, ROE, ROCE, EPS, book value, dividend yield and industry benchmarks, allowing a more grounded Univest stock analysis.

Accretion Pharmaceuticals Ltd. Share Price Today: Within 2% of 52-Week High

Metric	Value
LTP at 2% Qualification	Rs 190
Market Capitalisation	Rs 211.26 crore
52-Week High Position	Trading within 2% of its 52-week high

Accretion Pharmaceuticals Ltd. (ACCPL-ST) traded at Rs 190. Reported volume was 0.

Accretion Pharmaceuticals Ltd. Share Price Today is Rs 190, which is also the event-time last traded price captured by the Univest screener when the stock qualified for trading within 2% of its 52-week high. The event was recorded on 11 August 2026 at 9:30:37 AM IST, and the article was prepared shortly after at 9:30:38 AM IST, keeping the price context tightly aligned with the screening signal.

The main takeaway from the supplied price data is not the size of an intraday swing, but the location of the stock on its broader one-year range. A share trading close to its yearly high typically draws attention because it suggests the market is assigning a relatively firm price level to the business at that point in time. For a company with a market capitalisation of Rs 211.26 crore, that attention can become more pronounced because price positioning often gets examined alongside profitability ratios and relative valuation.

Investors following Accretion Pharmaceuticals Ltd. Stock News should also note an important boundary around the event. The Univest screen confirms proximity to the 52-week high, not a touch, not a breach and not a breakout. Since the exact 52-week high reference price was not supplied for publication, the relevant fact remains that the stock is near its one-year peak zone. From here, the more useful question becomes whether the underlying fundamentals and relative sector metrics justify continued attention.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 211.26 crore
P/E Ratio	21.85x
P/B Ratio	4.05x
ROE	27.18%
ROCE	12.62%
EPS	Rs 8.7
Book Value Per Share	Rs 46.91
Dividend Yield	0%

Accretion Pharmaceuticals Ltd. was valued at a P/E ratio of 21.85x, a P/B ratio of 4.05x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 27.18% and ROCE of 12.62%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 8.7, book value per share of Rs 46.91, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	21.85x
Benchmark Median P/E	18.46x
Benchmark Average P/E	52.81x
Benchmark P/E Range	0x to 3,396.3x
Company P/B Ratio	4.05x
Benchmark Median P/B	1.78x
Company ROE	27.18%
Benchmark Median ROE	10.21%
Company ROCE	12.62%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 211.26 crore
Benchmark Median Market Cap	Rs 146.63 crore

Accretion Pharmaceuticals Ltd. (ACCPL-ST) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a P/E ratio of 21.85x, which is above the benchmark median of 18.46x, a difference of +18.36%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a ROE of 27.18%, which is above the benchmark median of 10.21%, a difference of +166.21%. Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a ROCE of 12.62%, which is below the benchmark median of 12.98%, a difference of -2.77%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Coral Laboratories Ltd.	CORALAB	206.46	12.6	0.99	10.74	13.35
Accretion Nutraveda Ltd.	ANL	216.48	42.71	6.86	106.65	21.4
Gennex Laboratories Ltd.	GENNE	217.44	13.39	0.99	10.71	13.24
Sanjivani Paranteral Ltd.	SANJIVIN	237.33	33.35	4.77	0	266.43
BIO MEDICA LABORATORIES L	BMLL-SM	185.98	15.94	10.26	13.67	10.17

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a P/E ratio of 21.85x compared with the displayed peer median of 15.94x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.18% compares with a peer median of 10.74% across the companies shown in the table. ROCE stood at 12.62% versus the displayed peer median of 13.35%, providing a capital-efficiency comparison. Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a market capitalisation of Rs 211.26 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching Accretion Pharmaceuticals Ltd.

• The stock qualified on the Univest screener at Rs 190 and is trading within 2% of its 52-week high, putting Accretion Pharmaceuticals Ltd. Share Price on momentum watchlists.
• Market capitalisation of Rs 211.26 crore places the company in a small-cap bracket where price positioning often attracts close scrutiny.
• P/E of 21.85 is above the same-industry median of 18.46, while P/B of 4.05 is above the median of 1.78, pointing to a valuation premium versus the middle of the industry set.
• ROE of 27.18 is substantially above the industry median of 10.21, while ROCE of 12.62 is slightly below the median of 12.98, creating a nuanced profitability profile.
• Peer comparisons show the company sits in a similar size band to several Pharmaceuticals & Drugs names, but with stronger ROE than many of them.

About Accretion Pharmaceuticals Ltd.

Accretion Pharmaceuticals Ltd. is a listed company in the Healthcare sector, classified under the Pharmaceuticals & Drugs industry. Based on the supplied company context, the stock is part of India’s pharmaceutical-linked listed universe, where investors commonly track earnings multiples, book value, return ratios and market-cap positioning alongside price behaviour.

In practical terms, that industry classification places the company among businesses that are generally assessed through profitability measures such as ROE and ROCE, valuation indicators such as P/E and P/B, and relative standing against direct listed peers. For Accretion Pharmaceuticals Ltd. Share Price, the current attention comes not only from its proximity to a 52-week high, but also from the fact that its valuation and profitability metrics can be compared directly with a large same-industry sample and with several similarly sized peers.

As a result, the company is currently being watched through the combined lens of stock price strength, industry-relative valuation and return ratios rather than through any verified event-specific catalyst in the supplied Univest data.

Track Accretion Pharmaceuticals Ltd. Share Price on Univest

Use Accretion Pharmaceuticals Ltd. (ACCPL-ST) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

On Univest, users can track Accretion Pharmaceuticals Ltd. Share Price in real time along with 52-week levels, market capitalisation, valuation ratios, profitability indicators and peer comparisons. Univest also helps users follow broader stock analysis by combining share price movement with fundamentals, industry benchmarks and market insights in one place.

For investors who want to keep Accretion Pharmaceuticals Ltd. Share Price Today in context, Univest provides a structured way to monitor where the stock stands versus its one-year range, how its P/E and P/B compare with the Pharmaceuticals & Drugs industry, and how its ROE and ROCE stack up against similarly sized listed peers.

Frequently Asked Questions

What is Accretion Pharmaceuticals Ltd. Share Price today?

Ans. Accretion Pharmaceuticals Ltd. Share Price today is Rs 190, which is also the event-time last traded price captured by the Univest screener on 11 August 2026. The stock was identified as trading within 2% of its 52-week high.

Why is Accretion Pharmaceuticals Ltd. Share Price in focus?

Ans. The stock is in focus because Univest identified it trading within 2% of its 52-week high. That kind of price positioning often draws attention to valuation, profitability and peer comparisons, especially for a Rs 211.26 crore company.

What is the market capitalisation of Accretion Pharmaceuticals Ltd.?

Ans. Accretion Pharmaceuticals Ltd. has a market capitalisation of Rs 211.26 crore. Within its same-industry comparison set, that is above the median market cap of Rs 146.63 crore but below the average of Rs 502.14 crore.

Is Accretion Pharmaceuticals Ltd. expensive on P/E and P/B?

Ans. The stock trades at a P/E of 21.85 versus the industry median of 18.46 and at a P/B of 4.05 versus the median of 1.78. That indicates a valuation premium to the middle of the same-industry sample.

How profitable is Accretion Pharmaceuticals Ltd. on ROE and ROCE?

Ans. Accretion Pharmaceuticals Ltd. reports ROE of 27.18 and ROCE of 12.62. ROE is well above the industry median of 10.21, while ROCE is slightly below the median of 12.98, creating a mixed but informative profitability profile.

How does Accretion Pharmaceuticals Ltd. compare with similar peers?

Ans. Against peers such as Coral Laboratories, Gennex Laboratories and BIO MEDICA LABORATORIES L, the company shows stronger ROE at 27.18. Its P/E of 21.85 sits above some peers, while market cap at Rs 211.26 crore remains broadly comparable.

What do EPS, book value and dividend yield show for Accretion Pharmaceuticals Ltd.?

Ans. The supplied data shows EPS of 8.7, book value per share of Rs 46.91 and dividend yield of 0. Together, these indicate current earnings per share, accounting net worth per share and no indicated yield support.

Which sector and industry does Accretion Pharmaceuticals Ltd. belong to?

Ans. Accretion Pharmaceuticals Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. Univest compares it with a same-industry benchmark of 136 companies, within a broader Healthcare universe of 196 companies.